1Suzuki Y,Zhang H,Saito N,et al.Glucagon-like peptide-1 activates protein kinase C through Ca2+-dependent activation of phospholipaseC in insulin-secreting cells[J].J Biol Chem,2006,281(39):28499.
2Sturis J,Gotfredsen CF,Romer J,et al.GLP-1 derivative liraglutide in rats with β-cell deficiencies:influence of metabolic state on β-cell mass dynamics[J].Br Pharnacol,2003,140(1):123.
3Koizumi M,Doi R,Fujimoto K,et al.Pancreatic epithelial cells can be converted into insulin-producing cells by GLP-1 in conjunction with virus-mediates gene transfer of pdx-1[J].Surgery,2005,138(2):125.
4Farilla L,Hui H,Bertolotto C,et al.Glucagon-like-peptide-1 promotes silet cell growth and inhibits apoptosis in Zucker diabetic rats[J].Endocrinology,2002,143(11):4397.
5Prigeon RL,Quddusi S,Pety B,et al.Suppression of glucose production by GLP-1 independent of islet hormones:a novel extrapancreatic effect[J].Am J Physiol Endocrinol Metab,2003,285(4):E701.
6Dardevet D,Moore MC,Neal D,et al.Insulin-independent effects of GLP-1 on canine liver glucose metabolism:duration of infusion and involvement of hepatoportal region[J].Am J Physiol Endocrinol Metab,2004,287(1):E75.
7Ozyazgan S,Kutluata N,Afsar S,et al.Effect of glucagonlike peptide-1(7-36) and exendin-4 on the vascular rea tivity in streptozotocin/nicotinamide-induced diabetic rats[J].Pharmacology,2005,74(3):119.
8Nystrom T,Gutniak MK,Zhang Q,et al.Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease[J].Am J Physiol Endocrinol Metab,2004,287(6):E1209.
9Lugari R,Dei Cas A,Ugolotti D,et al.Evidence for early impairment of glucagon like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes[J].Horm Metab Res,2002,34(3):150.
10Bock T,Pakkenberg B,Buschard K.The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211[J].APMIS,2003,111(12):1117.
5YANG W Y, et al. Prevalence of diabetes among men and women in China [J]. N Engl J Med, 2010, 362 (12) : 1090- 1101.
6Suzuki Y, Zhang H, Saito N, et al. Glucagon-like peptide 1 activates protein kinase C through Ca2+ -dependent acti- vation of phospholipase C in insulin-secreting cells[J]. J Biol Chem, 2006,281 (39) : 284.
7Sturis J, Gotfredsen CF, Rcmer J, et al. GLP-1 deriva- tive liraglutide in rats with beta-cell deficiencies: influ- ence of metabolic state on beta-cell mass dynamics[J].Br JPharmacol, 2003,140( 1 ) : 123.
8Robles GI, Singh-Franco D. A review of exenatide as ad- junctive therapy in patients with type 2 diabetes [J]. Drug Des Devel Ther, 2009,3 : 219.
9Nielsen LL, Young AA, Parkes DG. Pharmacology of ex- enatide (synthetic exendin-4) : a potential therapeutic for improved glycemic control of type 2 diabetes[J]. Regul Pept,2004, 117(2) :77.
10Flint A, Raben A, Astrup A, et al. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans [J]. J Clin Invest, 1998,101 ( 3 ) : 515.
